Corporate News tagged:
Stem Cells
Oct 20, 2025
REPROCELL and Histocell Achieve GMP Certification for Manufacturing Process of Clinical-Grade iPSC Master and Working Cell Banks Using StemRNA™ Clinical iPSCs
REPROCELL and Histocell achieve GMP certification for clinical-grade iPSC manufacturing, advancing regenerative medicine and cell therapy production under EU regulations.
Jul 22, 2025
REPROCELL Announces U.S. FDA Drug Master File Submittal for StemRNA™ Clinical iPSC Seed Clones
REPROCELL is pleased to announce the successful submittal of its StemRNA™ Clinical iPSC Seed Clones with the U.S. Food and Drug Administration (FDA) via a Type II Drug Master File (DMF).
Jul 02, 2025
Scottish Health Minister Visits REPROCELL Japan to Strengthen Life Sciences Collaboration
Scottish Health Minister Neil Gray visits REPROCELL Japan to enhance life sciences collaboration, highlighting strong ties and innovative healthcare advancements between Scotland and Japan.
May 05, 2025
REPROCELL Launches Immune Modulated iPSC Products
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
Apr 25, 2025
Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment "Stemchymal®"
REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc., reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy "Stemchymal®". REPROCELL holds the exclusive commercialization license agreement for Stemchymal in Japan for the treatment of Spinocerebellar Ataxia (SCA).
Feb 06, 2025
Gameto Announces FDA IND Clearance for Fertilo utilizing REPROCELL’s StemRNA™ Clinical Seed iPSCs
Gameto's FDA IND clearance for Fertilo marks a milestone as the first iPSC-based therapy enters U.S. Phase 3 trials, leveraging REPROCELL’s StemRNA™ Clinical Seed iPSCs.
Jan 14, 2025
World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body
REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology.
Jan 10, 2025
PRESS RELEASE: Qkine announces partnership with REPROCELL: Global distributorship for high quality bioactive proteins for stem cell culture
Qkine Ltd., and REPROCELL Inc., have partnered to globally distribute high-quality proteins such as growth factors and cytokines manufactured by Qkine.
Jul 22, 2024
PRESS RELEASE: Bioserve India Launches Advanced Stem Cell Products
Discover Bioserve India's advanced stem cell products, supporting innovation in research and drug development.
May 30, 2024
REPROCELL USA Inaugurates GMP Manufacturing Facility for Stem Cells
REPROCELL USA unveils GMP manufacturing facility for hiPSC and hMSC, revolutionizing stem cell therapy with closed-system technology.
May 16, 2024
PRESS RELEASE: Our StemRNA Clinical Seed iPSCs Power Breakthrough in Women's Health!
An exciting breakthrough in women's health with our StemRNA Clinical Seed iPSCs powering innovative fertility treatment by Gameto.
Apr 18, 2024
New from REPROCELL: GMP Grade Stem Cell Master Cell Bank Service Expansion
REPROCELL announces the acquisition of a self-contained GMP system to expand our GMP capabilities.
Jan 31, 2024
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.
Jan 15, 2024
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.
Dec 15, 2023
End of 2023 Newsletter
Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.
Jul 11, 2023
Vernal Biosciences Announces Partnership With REPROCELL: Exclusive Distributorship in Japan for mRNA and LNP Formulation Services
Vernal Biosciences, a leader in mRNA and LNP manufacturing, and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to provide mRNA services in Japan at scale for research and clinical applications
May 25, 2023
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
May 23, 2023
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
REPROCELL will now offer CDMO services to manufacture ATMPs generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
Nov 23, 2022
REPROCELL invests in Histocell, S.L. a Spain-based CDMO
REPROCELL Inc. decided to invest in Histocell S.L. to strengthen its clinical induced pluripotent stem cell (iPSC) service offerings.
Sep 02, 2021
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.